SMARCA1 and pancreatic neoplasm: In pancreatic cancer, pancreatic cells with SWI/SNF dysfunction exhibit significantly increased sensitivity to DNA-damaging agents, particularly DNA cross-linking agents (such as cisplatin and oxaliplatin) [249].